Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, ...

US pharma major Eli Lilly today announced detailed results from QWINT-1, QWINT-3, and QWINT-4 Phase III clinical trials ...

An experimental once-weekly insulin known as efsitora has shown comparable effectiveness to daily insulin regimens in managing blood sugar levels among adults with type 2 diabetes, according to ...

Once-weekly efsitora vs once-daily degludec was associated with comparable glycemic control outcomes and improved ...

Biocon Biologics Ltd. (BBL) on Monday announced that its Malaysian subsidiary, Biocon Sdn. Bhd., has surpassed the supply of ...

compared with once-daily insulin glargine U100 (8.28% to 7.08%) over 52 weeks in insulin-naïve adults with type 2 diabetes (the estimated between-group difference of -0.03 percentage points, 95% CI -0 ...

Eli Lilly will likely draw investor focus on Monday as the company said its investigational once-weekly insulin efsitora alfa met primary endpoints across three Phase 3 trials — QWINT-1, QWINT-3, and ...

Prescriptions for insulin glargine-yfgn (Semglee) rapidly increased when its status switched from a standard biosimilar to the first interchangeable insulin biosimilar, an economic evaluation ...

Biosimilar insulin glargine access in Europe correlates with significant price reductions of originator products, enhancing affordability and accessibility. The study observed a 21.6% average ...

Results from the QWINT-1 and QWINT-3 trials found that insulin-naïve patients achieved similar reductions in A1C levels using once-weekly efsitora compared to daily insulin glargine and degludec.

Find patient medical information for Insulin Glargine on WebMD including its uses, side effects and safety, interactions, pictures, warnings, and user ratings ...